Citius oncology, inc. CTOR.US Overview
CTOR AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
CTOR Current Performance
-
Citius oncology, inc.
1.60%
Avg of Sector
0.32%
S&P500
CTOR Key Information
CTOR Revenue by Segments
Browsing restrictions can be lifted for a fee.
CTOR Net Income
Browsing restrictions can be lifted for a fee.
CTOR Cash Flow
Browsing restrictions can be lifted for a fee.
CTOR Profit Margin
Browsing restrictions can be lifted for a fee.
CTOR PE Ratio River
Browsing restrictions can be lifted for a fee.
CTOR Financial Forecast
Browsing restrictions can be lifted for a fee.
CTOR Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
CTOR Profile
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Price of CTOR
CTOR FAQ
When is CTOR's latest earnings report released?
The most recent financial report for Citius oncology, inc. (CTOR) covers the period of 2025Q2 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CTOR's short-term business performance and financial health. For the latest updates on CTOR's earnings releases, visit this page regularly.
How much cash does CTOR have?
At the end of the period, Citius oncology, inc. (CTOR) held Total Cash and Cash Equivalents of 112, accounting for 0 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is CTOR's EPS continuing to grow?
According to the past four quarterly reports, Citius oncology, inc. (CTOR)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.11. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of CTOR?
Citius oncology, inc. (CTOR)'s Free Cash Flow (FCF) for the period is 0, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 100% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.